These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 3060267)

  • 1. Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations.
    Pimm MV
    Crit Rev Ther Drug Carrier Syst; 1988; 5(3):189-227. PubMed ID: 3060267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cancer therapy by using bispecific antibody].
    Azuma A; Niitani H; Okumura K
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1535-42. PubMed ID: 1872618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-conjugated monoclonal antibodies for the treatment of cancer.
    Lambert JM
    Curr Opin Pharmacol; 2005 Oct; 5(5):543-9. PubMed ID: 16087399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies in the therapy of colon cancer.
    Welt S; Ritter G
    Semin Oncol; 1999 Dec; 26(6):683-90. PubMed ID: 10606261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted anti-tumor agents and their cytotoxicity on gastric cancer cells in vitro.
    Li S; Zhang XY; Chen XT; Fan DM; Tan LS; Pan HZ; Huang LQ
    Chin Med J (Engl); 1990 May; 103(5):376-9. PubMed ID: 2118053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity.
    Pietersz GA; Kanellos J; McKenzie IF
    Cancer Res; 1988 Aug; 48(16):4469-76. PubMed ID: 3260814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Targeting of antitumor drugs with monoclonal antibodies].
    Monneret C; Florent JC
    Bull Cancer; 2000 Nov; 87(11):829-38. PubMed ID: 11125291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity and selectivity of ricin toxin A chain-monoclonal antibody 791T/36 conjugates against human tumor cell lines.
    Embleton MJ; Byers VS; Lee HM; Scannon P; Blackhall NW; Baldwin RW
    Cancer Res; 1986 Nov; 46(11):5524-8. PubMed ID: 3489523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody conjugate therapeutics: challenges and potential.
    Teicher BA; Chari RV
    Clin Cancer Res; 2011 Oct; 17(20):6389-97. PubMed ID: 22003066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The design of cytotoxic-agent-antibody conjugates.
    Ghose T; Blair AH
    Crit Rev Ther Drug Carrier Syst; 1987; 3(4):263-359. PubMed ID: 2435417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-cytotoxic agent conjugates for cancer therapy.
    Chen J; Jaracz S; Zhao X; Chen S; Ojima I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):873-90. PubMed ID: 16296784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
    Ojima I
    Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
    Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
    Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigations with monoclonal antibody drug (anthracycline) conjugates.
    Hermentin P; Seiler FR
    Behring Inst Mitt; 1988 Apr; (82):197-215. PubMed ID: 3044339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies.
    Seon BK
    Cancer Res; 1984 Jan; 44(1):259-64. PubMed ID: 6606488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody therapy of cancer.
    Weiner LM
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):43-51. PubMed ID: 10561017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.
    McDonagh CF; Turcott E; Westendorf L; Webster JB; Alley SC; Kim K; Andreyka J; Stone I; Hamblett KJ; Francisco JA; Carter P
    Protein Eng Des Sel; 2006 Jul; 19(7):299-307. PubMed ID: 16644914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.